Vascular Perfusion Solutions is advancing organ transplantation with VP.S ENCORE®, a premarket cardiac perfusion system designed to extend donor heart viability up to eight hours.
More than 100,000 patients are awaiting transplant. Yet standard cold storage preserves donor hearts for only up to 4 hours. As a result, only 30% of available donor hearts are transplanted.
VP.S ENCORE® is designed to extend donor heart viability, limit ischemic injury, and support more flexible timing and logistics during organ recovery and transport.
Built to address the limitations of conventional cold storage, VP.S ENCORE® represents a new approach to heart preservation technology — operating without blood or blood products, using FDA-approved perfusate and passive cooling.
Passive cooling. FDA-approved perfusate. No blood or blood products required. Designed to be handled by a single operator and deployed anywhere transplant care happens.
Designed to streamline workflows using familiar, standardized materials while eliminating system components that can delay or complicate setup.
Compact, built for single-person handling, and powered by a long-lasting battery — supports uninterrupted preservation without specialized transport or additional staff.
A built-in cold storage fallback protects the organ if circulation is interrupted — helping maintain hypothermic conditions while minimizing ischemic risk across longer distances.
Explore the engineering, clinical rationale, and preclinical data behind the device.
VP.S ENCORE® is being developed to address the limits of current preservation methods by supporting donor heart viability during transport and extending the window beyond standard cold storage.
Learn MoreOPOs face rigorous outcome measures tied to donation rates, organ utilization, and timely transplant performance. VP.S ENCORE® supports these demands with a portable, bloodless system to reduce transport constraints and expand access to viable donor hearts.
Learn MoreExplore publications, scientific data, and educational resources that offer a closer look at hypothermic perfusion, organ preservation technology, and the broader VP.S ENCORE® research platform.
A comparative look at hypothermic and normothermic perfusion — including clinical outcomes, device footprint, and the tradeoffs shaping the next decade of transplant logistics.
Read MoreVascular Perfusion Solutions is advancing research initiatives in collaboration with leading cardiac centers, government institutions, and more. Ongoing work includes organ preservation science, pediatric heart preservation, kidney preservation, gene delivery during perfusion, and vascularized composite tissue preservation.
Connect with our team to learn more about VP.S ENCORE® and explore the technology in development.
Vascular Perfusion Solutions is focused on advancing cardiac graft preservation through simplified hypothermic machine perfusion technology. The company takes a data-driven, evidence-based approach to research and development, working closely with leading scientists, engineers, and industry advisors to rigorously evaluate and refine its technology.
Its flagship system, VP.S ENCORE®, reflects this commitment to scientific integrity and practical innovation in cardiac transplantation.
About Us